eFFECTOR Therapeutics, Inc. (EFTR)
(Delayed Data from NSDQ)
$1.31 USD
-0.07 (-5.07%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $1.31 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for eFFECTOR Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 4 | 1 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 4 | 1 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 34 | 36 | 33 | 0 | 0 |
Income After Depreciation & Amortization | -34 | -32 | -32 | 0 | 0 |
Non-Operating Income | 1 | 12 | 49 | 0 | NA |
Interest Expense | 3 | 2 | 2 | 0 | NA |
Pretax Income | -36 | -23 | 16 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -36 | -23 | 16 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -36 | -23 | 16 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -34 | -32 | -32 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -34 | -32 | -32 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.19 | 1.65 | 1.44 | NA | NA |
Diluted EPS Before Non-Recurring Items | -16.37 | -13.75 | 11.00 | NA | NA |
Diluted Net EPS (GAAP) | -16.37 | -13.75 | 11.00 | -0.01 | NA |
Fiscal Year end for eFFECTOR Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 8.40 | 8.59 | 7.86 | 7.85 | 9.54 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.40 | -8.59 | -7.86 | -7.85 | -9.54 |
Non-Operating Income | 0.31 | 0.23 | 0.30 | 0.21 | 0.21 |
Interest Expense | 0.75 | 0.76 | 0.75 | 0.72 | 0.69 |
Pretax Income | -8.83 | -9.13 | -8.30 | -8.36 | -10.01 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.83 | -9.13 | -8.30 | -8.36 | -10.01 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.83 | -9.13 | -8.30 | -8.36 | -10.01 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 4.08 | 2.67 | 2.47 | 1.91 | 1.68 |
Diluted EPS Before Non-Recurring Items | -2.16 | -3.42 | -3.25 | -4.25 | -6.00 |
Diluted Net EPS (GAAP) | -2.16 | -2.87 | -3.25 | -4.25 | -6.00 |